Purdue Pharma is expected to face a forfeiture of $225 million as part of a settlement with the Justice Department. This development is seen as a pivotal moment in the company's ongoing legal challenges.
The ruling by the U.S. judge is anticipated to facilitate a substantial settlement, which could have implications for other parties involved in similar legal issues.
In related news, Merck and Eisai are reportedly encountering setbacks in their own legal cases, highlighting the broader challenges facing the pharmaceutical industry.